Distraught mother Seny Zogba was working in a cassava field in Bossou, in Guinea, when a chimp sunk his teeth into her and stole her eight-month-old baby, named as Yoh Hélène. The little girl ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cassava faces a cash burn of $80-$90 million in the second half of 2024, which will significantly reduce its current cash runway. Due to data integrity issues and unproven efficacy, I maintain a ...

The MARA team also paid a brief visit to the proposed Agriculture Field Experimental Station at the Tenaru site, earmarked for an Agriculture and Livestock research centre, training centre, and pig ...

Cassava Sciences and two former executives agreed to pay more than $40 million in a settlement with the SEC. The SEC said that Cassava made misleading statements about a clinical trial of its ...

The research behind Cassava Sciences’ Alzheimer’s drug candidate, simufilam, and the idea of targeting a brain protein called filamin, is based on a series of papers from a group at CUNY and ...

Alzheimer’s drug developer Cassava Sciences agreed Thursday to pay $40 million to settle regulatory claims that it misled investors about the results of a clinical trial that showed promise for ...

Cassava Sciences faced a $40 million penalty to focus on Simufilam's development following SEC charges over misleading trial data. Cassava Sciences completed ReTHINK Phase 3 trial with 804 ...

WASHINGTON, Sept 26 (Reuters) - Shares of Cassava Sciences (SAVA.O), opens new tab fell 10% in post-market trading on Thursday after the U.S. Securities and Exchange Commission charged the ...

Cassava, without admitting or denying the SEC’s allegations, agreed to pay a monetary penalty of $40 million. The Company cooperated fully with the SEC’s investigation and has implemented ...

AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on ...

AUSTIN, Texas, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the completion of a third interim ...